论文部分内容阅读
异基因造血干细胞移植是有望治愈血液系统恶性疾病的唯一治疗手段,但因人类白细胞抗原(HLA)相合供体的缺乏而受到严重制约[1-2]。对于HLA相合的非亲缘无关供体,不到30%的患者能够寻找到合适的供者,尤其是稀有人种因受种族背景等影响,找到合适供体的概率更低[3]。因此,寻找新的造血干细胞来源显得尤为重要。非血缘脐血(unrelated umbilical cord blood,UCB)就是一种新
Allogeneic hematopoietic stem cell transplantation is the only treatment that is expected to cure malignant diseases of the hematological system, but is severely restricted by the lack of human leukocyte antigen (HLA) donor donors [1-2]. Less than 30% of HLA-matched, unrelated unrelated donors can find suitable donors, especially rare ones due to their racial background and less likely to find a suitable donor [3]. Therefore, looking for new sources of hematopoietic stem cells is particularly important. Non-blood cord blood (unrelated umbilical cord blood, UCB) is a new